DT-Web

DB00072 - Trastuzumab


Identification
Name Trastuzumab
Accession Number DB00072 (BIOD00098, BTD00098)
Type biotech
Description A recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein. Produced in CHO cell culture.*
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight 145531.5000
Groups approved
Monoisotopic Weight Not Available
Pharmacology
Indication For treatment of early stage HER2-positive breast cancer, or metastatic breast cancer that substantially overexpress HER2.
Mechanism of action Trastuzumab binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells.
Absorption Not Available
Protein binding Not Available
Biotransformation Most likely removed by opsonization via the reticuloendothelial system.
Route of elimination Not Available
Toxicity Administration of trastuzumab can result in ventricular dysfunction and congestive heart failure. Risk of cardiotocity is especially elevated in patients recieving concurrent anthracycline or cyclophosphamide therapy.
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions
Drug Mechanism of interaction
Abatacept Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Abciximab Abciximab may increase the risk of a hypersensitivy reaction to Trastuzumab.
Adalimumab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Alemtuzumab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Altretamine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Amsacrine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Anakinra Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Asparaginase Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Azacitidine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Azathioprine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Basiliximab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Betamethasone Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Bleomycin Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Busulfan Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Capecitabine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Carboplatin Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Carmustine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Chlorambucil Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Cisplatin Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Cladribine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Clofarabine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Corticotropin Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Cortisone acetate Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Cyclophosphamide Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Cyclosporine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Cytarabine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Dacarbazine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Daclizumab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Dactinomycin Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Daunorubicin Trastuzumab may increase the cardiotoxicity of Daunorubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Denileukin diftitox Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Dexamethasone Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Docetaxel Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Doxorubicin Trastuzumab may increase the cardiotoxicity of Doxorubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Efalizumab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Epirubicin Trastuzumab may increase the cardiotoxicity of Epirubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Erlotinib Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Estramustine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Etanercept Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Etoposide Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Floxuridine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Fludarabine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Fludrocortisone Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Fluorouracil Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Gefitinib Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Gemcitabine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Hydrocortisone Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Hydroxyurea Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Ibritumomab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Idarubicin Trastuzumab may increase the cardiotoxicity of Idarubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Ifosfamide Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Imatinib Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Infliximab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Irinotecan Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Lenalidomide Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Lomustine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Mechlorethamine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Melphalan Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Mercaptopurine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Methotrexate Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Methylprednisolone Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Mitomycin Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Mitoxantrone Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Muromonab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Mycophenolate mofetil Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Mycophenolic acid Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Natalizumab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Nelarabine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Nilotinib Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Oxaliplatin Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Paclitaxel Trastuzumab may increase the risk of neutropenia and anemia. Concomitant therapy may also increase Trastuzumab serum concentration and decrease Paclitaxel serum concentrations. Monitor closely for adverse events and therapeutic response.
Pegaspargase Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Pentostatin Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Prednisolone Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Prednisone Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Procarbazine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Rilonacept Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Rituximab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Sirolimus Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Sorafenib Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Streptozocin Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Sunitinib Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Tacrolimus Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Temozolomide Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Temsirolimus Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Teniposide Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Thalidomide Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Thioguanine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Thiotepa Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Tofacitinib Trastuzumab, when used in combination with tofacitinib, may increase tofacitinib adverse effects, ie. neutropenic effects. It is recommended to monitor therapy.
Topotecan Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Tositumomab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Tretinoin Increased risk of leukopenia and anemia due to synergistic effects. Monitor for signs and symptoms of adverse events during concomitant therapy.
Triamcinolone Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Valrubicin Trastuzumab may increase the cardiotoxicity of Valrubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Vinblastine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Vincristine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Vinorelbine Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Food Interactions Not Available

Targets


Receptor tyrosine-protein kinase erbB-2
Name Receptor tyrosine-protein kinase erbB-2
Gene Name ERBB2
Pharmacological action yes
Actions antibody
References
  • Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. - Pubmed
  • Leveque D, Gigou L, Bergerat JP: Clinical pharmacology of trastuzumab. Curr Clin Pharmacol. 2008 Jan;3(1):51-5. - Pubmed
  • Lin A, Rugo HS: The role of trastuzumab in early stage breast cancer: current data and treatment recommendations. Curr Treat Options Oncol. 2007 Feb;8(1):47-60. - Pubmed
  • Treish I, Schwartz R, Lindley C: Pharmacology and therapeutic use of trastuzumab in breast cancer. Am J Health Syst Pharm. 2000 Nov 15;57(22):2063-76; quiz 2077-9. - Pubmed
DTHybrid score 0.839
Epidermal growth factor receptor
Name Epidermal growth factor receptor
Gene Name EGFR
Pharmacological action unknown
Actions Not Available
References
  • Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. - Pubmed
DTHybrid score 0.8246
Complement C1r subcomponent
Name Complement C1r subcomponent
Gene Name C1R
Pharmacological action unknown
Actions Not Available
References
  • Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. - Pubmed
  • Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. - Pubmed
DTHybrid score 1.5038
Complement C1q subcomponent subunit A
Name Complement C1q subcomponent subunit A
Gene Name C1QA
Pharmacological action unknown
Actions Not Available
References
  • Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. - Pubmed
  • Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. - Pubmed
DTHybrid score 1.5214
Complement C1q subcomponent subunit B
Name Complement C1q subcomponent subunit B
Gene Name C1QB
Pharmacological action unknown
Actions Not Available
References
  • Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. - Pubmed
  • Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. - Pubmed
DTHybrid score 1.5223
Complement C1q subcomponent subunit C
Name Complement C1q subcomponent subunit C
Gene Name C1QC
Pharmacological action unknown
Actions Not Available
References
  • Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. - Pubmed
  • Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. - Pubmed
DTHybrid score 1.5223
Complement C1s subcomponent
Name Complement C1s subcomponent
Gene Name C1S
Pharmacological action unknown
Actions Not Available
References
  • Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. - Pubmed
  • Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. - Pubmed
DTHybrid score 1.1386
High affinity immunoglobulin gamma Fc receptor I
Name High affinity immunoglobulin gamma Fc receptor I
Gene Name FCGR1A
Pharmacological action unknown
Actions Not Available
References
  • Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. - Pubmed
  • Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. - Pubmed
  • Curnow RT: Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):210-5. - Pubmed
DTHybrid score 1.6809
Low affinity immunoglobulin gamma Fc region receptor II-a
Name Low affinity immunoglobulin gamma Fc region receptor II-a
Gene Name FCGR2A
Pharmacological action unknown
Actions Not Available
References
  • Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. - Pubmed
  • Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. - Pubmed
  • Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8. - Pubmed
DTHybrid score 1.6042
Low affinity immunoglobulin gamma Fc region receptor II-b
Name Low affinity immunoglobulin gamma Fc region receptor II-b
Gene Name FCGR2B
Pharmacological action unknown
Actions Not Available
References
  • Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. - Pubmed
  • Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. - Pubmed
DTHybrid score 1.5993
Low affinity immunoglobulin gamma Fc region receptor II-c
Name Low affinity immunoglobulin gamma Fc region receptor II-c
Gene Name FCGR2C
Pharmacological action unknown
Actions Not Available
References
  • Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. - Pubmed
  • Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. - Pubmed
DTHybrid score 1.6097
Low affinity immunoglobulin gamma Fc region receptor III-B
Name Low affinity immunoglobulin gamma Fc region receptor III-B
Gene Name FCGR3B
Pharmacological action unknown
Actions Not Available
References
  • Bowles JA, Weiner GJ: CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods. 2005 Sep;304(1-2):88-99. - Pubmed
  • Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM: Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem. 2004 Dec 24;279(52):53907-14. Epub 2004 Oct 7. - Pubmed
  • Kubo M, Morisaki T, Kuroki H, Tasaki A, Yamanaka N, Matsumoto K, Nakamura K, Onishi H, Baba E, Katano M: Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer. Anticancer Res. 2003 Nov-Dec;23(6a):4443-9. - Pubmed
  • Yamaguchi Y, Hironaka K, Okawaki M, Okita R, Matsuura K, Ohshita A, Toge T: HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab. Anticancer Res. 2005 Mar-Apr;25(2A):827-32. - Pubmed
  • Xie Z, Guo N, Yu M, Hu M, Shen B: A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis. J Immunol Methods. 2005 Jan;296(1-2):95-101. Epub 2004 Nov 19. - Pubmed
DTHybrid score 1.5959
Low affinity immunoglobulin gamma Fc region receptor III-A
Name Low affinity immunoglobulin gamma Fc region receptor III-A
Gene Name FCGR3A
Pharmacological action unknown
Actions Not Available
References
  • Suzuki E, Niwa R, Saji S, Muta M, Hirose M, Iida S, Shiotsu Y, Satoh M, Shitara K, Kondo M, Toi M: A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clin Cancer Res. 2007 Mar 15;13(6):1875-82. - Pubmed
DTHybrid score 1.5955

Enzymes


Cytochrome P450 19A1
Name Cytochrome P450 19A1
Gene Name CYP19A1
Actions inhibitor
References
  • Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. - Pubmed
DTHybrid score 0.3968

Predictions


Id Partner name Gene Name Score
75 B-lymphocyte antigen CD20 MS4A1 0.368
724 Interleukin-2 receptor alpha chain IL2RA 0.2111
717 Interleukin-2 receptor subunit beta IL2RB 0.2111
777 Tumor necrosis factor TNF 0.1699
744 Myeloid cell surface antigen CD33 CD33 0.1557
93 CAMPATH-1 antigen CD52 0.1474
757 Fusion glycoprotein F0 F 0.147
4875 Fusion glycoprotein F0 F 0.147
1588 Multidrug resistance protein 1 ABCB1 0.1346
1733 Vitronectin VTN 0.1334
793 T-cell surface antigen CD2 CD2 0.1302
4512 Cytochrome P450 3A4 CYP3A4 0.1258
5901 T-cell surface glycoprotein CD3 zeta chain CD247 0.1247
1789 Lymphotoxin-alpha LTA 0.1247
302 T-cell surface glycoprotein CD3 epsilon chain CD3E 0.1247
5900 T-cell surface glycoprotein CD3 gamma chain CD3G 0.1247
5899 T-cell surface glycoprotein CD3 delta chain CD3D 0.1246
1269 Tumor necrosis factor receptor superfamily member 1B TNFRSF1B 0.1246
1783 Intercellular adhesion molecule 1 ICAM1 0.1174
647 Integrin alpha-4 ITGA4 0.1173
488 Integrin alpha-IIb ITGA2B 0.1156
2039 Integrin beta-3 ITGB3 0.1139
572 Integrin alpha-L ITGAL 0.1081
183 Vascular endothelial growth factor A VEGFA 0.1057
955 Complement C5 C5 0.1033
5898 Complement C3 C3 0.103
1732 ATP-binding cassette sub-family G member 2 ABCG2 0.0913
4118 Cytochrome P450 3A5 CYP3A5 0.0847
5300 Antigen peptide transporter 1 TAP1 0.0726
554 Low-density lipoprotein receptor LDLR 0.0664
146 Androgen receptor AR 0.0618
290 Prostaglandin G/H synthase 2 PTGS2 0.0567
4924 Cytochrome P450 2C8 CYP2C8 0.0491
6016 Cytochrome P450 2C19 CYP2C19 0.0486
933 Proto-oncogene tyrosine-protein kinase Src SRC 0.0482
4200 Cytochrome P450 1A2 CYP1A2 0.0328
136 Estrogen receptor ESR1 0.0319
756 Sex hormone-binding globulin SHBG 0.0274
4757 Cytochrome P450 2C9 CYP2C9 0.0263
6017 Cholesterol side-chain cleavage enzyme, mitochondrial CYP11A1 0.024
1181 Alpha-1-acid glycoprotein 1 ORM1 0.0224
260 Cytochrome P450 51 ERG11 0.0214
761 Cytochrome P450 51 ERG11 0.0214
3163 Cytochrome P450 51 cyp51 0.0214
5718 Cytochrome P450 2A6 CYP2A6 0.0213
587 Serum albumin ALB 0.0211
4119 Cytochrome P450 2D6 CYP2D6 0.0208
563 Thyroid peroxidase TPO 0.0207
6030 Cytochrome P450 2B6 CYP2B6 0.0205
4116 Dihydropteroate synthetase Not Available 0.0199
226 Gonadotropin-releasing hormone receptor GNRHR 0.0193
6013 Cytochrome P450 2E1 CYP2E1 0.0191
6024 Cytochrome P450 1A1 CYP1A1 0.0189
148 Lutropin-choriogonadotropic hormone receptor LHCGR 0.0175
660 T-cell surface glycoprotein CD1a CD1A 0.0172
6063 Major histocompatibility complex class I-related gene protein MR1 0.0172
5955 T-cell surface glycoprotein CD4 CD4 0.0172
6065 Integrin beta-1 ITGB1 0.0172
6066 Integrin alpha-V ITGAV 0.0172
3950 Cell division protein kinase 9 CDK9 0.0171
3968 Cell division protein kinase 8 CDK8 0.0171
5787 Angiopoietin-1 receptor TEK 0.0158
3959 Cell division protein kinase 4 CDK4 0.015
3482 Cell division protein kinase 7 CDK7 0.0148
6104 Dimethylaniline monooxygenase [N-oxide-forming] 1 FMO1 0.0147
6107 Cytochrome P450 3A7 CYP3A7 0.0142
3955 Cell division protein kinase 6 CDK6 0.0138
942 T-lymphocyte activation antigen CD86 CD86 0.0138
6101 Dimethylaniline monooxygenase [N-oxide-forming] 3 FMO3 0.0127
1898 Cytochrome P450 1B1 CYP1B1 0.0125
1742 D-HSCDK2 CDK2deltaT 0.0119
1771 Cell division control protein 2 homolog CDK1 0.0119
3321 Cell division control protein 2 homolog CRK2 0.0119
6044 Serum paraoxonase/lactonase 3 PON3 0.0118
1058 Cell division protein kinase 5 CDK5 0.0116
1284 Nuclear receptor subfamily 1 group I member 2 NR1I2 0.0099
614 Progesterone receptor PGR 0.0096
862 Multidrug resistance-associated protein 1 ABCC1 0.0091
805 Cytochrome P450 11B1, mitochondrial CYP11B1 0.0088
1995 Sodium channel protein type 9 subunit alpha SCN9A 0.0085
3923 Cholinesterase BCHE 0.0083
3941 Amine oxidase [flavin-containing] A MAOA 0.0081
871 Glucocorticoid receptor NR3C1 0.008
869 Estrogen receptor beta ESR2 0.0079
3957 Adenosine deaminase ADA 0.0079
596 3-oxo-5-alpha-steroid 4-dehydrogenase 1 SRD5A1 0.0078
1680 Solute carrier family 2, facilitated glucose transporter member 1 SLC2A1 0.0078
1152 Glycogen phosphorylase, muscle form PYGM 0.0077
6022 UDP-glucuronosyltransferase 1-1 UGT1A1 0.0074
6106 Cytochrome P450 2C18 CYP2C18 0.0074
3939 Amine oxidase [flavin-containing] B MAOB 0.007
380 Cytochrome P450 17A1 CYP17A1 0.007
1656 CYP2B protein CYP2B 0.0068
6023 Cytochrome P450 11B2, mitochondrial CYP11B2 0.0065
2240 Cell division protein kinase 2 CDK2 0.0064
198 Sodium channel protein type 10 subunit alpha SCN10A 0.0063
1649 Small inducible cytokine A2 CCL2 0.0062
6142 Solute carrier family 22 member 8 SLC22A8 0.0062
6139 Solute carrier organic anion transporter family member 1A2 SLCO1A2 0.0061
6078 Neuronal acetylcholine receptor subunit beta-4 CHRNB4 0.006
217 Estradiol 17-beta-dehydrogenase 1 HSD17B1 0.0057
847 Mu-type opioid receptor OPRM1 0.0056
220 Sodium channel protein type 5 subunit alpha SCN5A 0.0055
6079 Neuronal acetylcholine receptor subunit alpha-3 CHRNA3 0.0054
3947 Xanthine dehydrogenase/oxidase XDH 0.005
144 Hemoglobin subunit alpha HBA1 0.0049
118 Organic cation/carnitine transporter 2 SLC22A5 0.0049
3809 Estrogen-related receptor gamma ESRRG 0.0048
564 Cellular retinoic acid-binding protein 1 CRABP1 0.0047
776 Bile salt export pump ABCB11 0.0047
6020 Aldehyde oxidase AOX1 0.0047
629 Alpha-2B adrenergic receptor ADRA2B 0.0047
5934 Cytochrome P450 26A1 CYP26A1 0.0047
1010 Cytochrome P450 51A1 CYP51A1 0.0046
1178 Adenosine A2a receptor ADORA2A 0.0045
1735 Canalicular multispecific organic anion transporter 1 ABCC2 0.0043
780 Retinoic acid receptor RXR-gamma RXRG 0.0043
229 Retinoic acid receptor beta RARB 0.0043
634 Squalene monooxygenase SQLE 0.0043
7196 Squalene monooxygenase ERG1 0.0043
730 Retinoic acid receptor alpha RARA 0.0042
872 Gamma-aminobutyric-acid receptor subunit alpha-1 GABRA1 0.004
462 Intermediate conductance calcium-activated potassium channel protein 4 KCNN4 0.004
459 Retinoic acid receptor RXR-alpha RXRA 0.004
88 Retinoic acid receptor RXR-beta RXRB 0.0039
162 Retinoic acid receptor gamma-1 RARG 0.0039
3830 Calreticulin CALR 0.0034
474 Acetylcholinesterase ACHE 0.0033
20 Prostaglandin G/H synthase 1 PTGS1 0.0033
6035 Nuclear receptor ROR-beta RORB 0.0032
6034 Hydroxyindole O-methyltransferase ASMT 0.0032
6036 Eosinophil peroxidase EPX 0.0032
6025 UDP-glucuronosyltransferase 1-4 UGT1A4 0.0029
765 Indoleamine 2,3-dioxygenase IDO1 0.0027
6031 Cytochrome P450 3A43 CYP3A43 0.0027
571 Melatonin receptor type 1A MTNR1A 0.0026
362 Melatonin receptor type 1B MTNR1B 0.0026
3810 Catechol O-methyltransferase COMT 0.0025
4604 Liver carboxylesterase 1 CES1 0.0025
4878 Glycoprotein hormones alpha chain CGA 0.0024
1072 Granzyme B GZMB 0.0024
4189 Alpha-galactosidase A GLA 0.0024
1052 Cytotoxic T-lymphocyte protein 4 CTLA4 0.0024
4889 Ig epsilon chain C region IGHE 0.0024
4877 Beta-mannanase man 0.0024
4871 Endo-beta-N-acetylglucosaminidase F3 endOF3 0.0024
4850 Beta-2-glycoprotein 1 APOH 0.0024
4852 Reticulon-4 receptor RTN4R 0.0024
4880 Membrane cofactor protein CD46 0.0024
4856 CD209 antigen CD209 0.0024
4869 Major capsid protein A430L 0.0024
4845 ADAM 33 ADAM33 0.0024
1563 Platelet glycoprotein Ib alpha chain GP1BA 0.0024
1354 Beta-glucuronidase GUSB 0.0024
442 Envelope glycoprotein gp41 0.0024
4859 Envelope glycoprotein env 0.0024
4882 Dipeptidyl aminopeptidase-like protein 6 DPP6 0.0024
4721 Beta-1,4-mannanase manA 0.0024
3352 Structural polyprotein Not Available 0.0024
3628 Structural polyprotein Not Available 0.0024
4892 Structural polyprotein Not Available 0.0024
5923 Microtubule-associated protein tau MAPT 0.0024
5924 Microtubule-associated protein 4 MAP4 0.0024
458 Neuronal acetylcholine receptor subunit alpha-10 CHRNA10 0.0023
267 Plasminogen activator inhibitor 1 SERPINE1 0.0023
1852 Microtubule-associated protein 2 MAP2 0.0023
7 Nitric oxide synthase, inducible NOS2 0.0022
6931 Calcium-activated potassium channel subunit beta-1 KCNMB1 0.0022
6933 Calcium-activated potassium channel subunit beta-4 KCNMB4 0.0022
6932 Calcium-activated potassium channel subunit beta-3 KCNMB3 0.0022
6934 Small conductance calcium-activated potassium channel protein 1 KCNN1 0.0022
6935 Small conductance calcium-activated potassium channel protein 2 KCNN2 0.0022
6936 Small conductance calcium-activated potassium channel protein 3 KCNN3 0.0022
6143 Solute carrier family 22 member 7 SLC22A7 0.0022
273 Apoptosis regulator Bcl-2 BCL2 0.0021
373 Transthyretin TTR 0.0021
1184 Interferon beta IFNB1 0.0021
6858 Inactive carboxylesterase 4 CES1P1 0.0021
4857 Zinc-alpha-2-glycoprotein AZGP1 0.0021
4193 Atrial natriuretic peptide clearance receptor NPR3 0.0021
4890 Hemagglutinin HA 0.0021
6566 Hemagglutinin Not Available 0.0021
4861 Interleukin-6 receptor alpha chain IL6R 0.0021
119 Carcinoembryonic antigen-related cell adhesion molecule 1 CEACAM1 0.0021
1379 Interleukin-12 subunit beta IL12B 0.0021
3837 Cytokine receptor common beta chain CSF2RB 0.0021
6221 Steroid hormone receptor ERR1 ESRRA 0.0021
1490 Solute carrier organic anion transporter family member 1B1 SLCO1B1 0.0021
6002 Prostaglandin E2 receptor EP4 subtype PTGER4 0.002
3444 Cyanovirin-N Not Available 0.002
18 High affinity immunoglobulin epsilon receptor subunit alpha FCER1A 0.002
1859 Prostatic acid phosphatase ACPP 0.002
2998 Sialic acid-binding Ig-like lectin 7 SIGLEC7 0.002
852 Heparin cofactor 2 SERPIND1 0.002
3258 Mannosyl-oligosaccharide alpha-1,2-mannosidase MSDC 0.002
3140 Hemagglutinin-neuraminidase HN 0.002
3609 Hemagglutinin-neuraminidase HN 0.002
6120 Cation-independent mannose-6-phosphate receptor IGF2R 0.002
2297 Genome polyprotein Not Available 0.002
2322 Genome polyprotein Not Available 0.002
2694 Genome polyprotein Not Available 0.002
2719 Genome polyprotein Not Available 0.002
2860 Genome polyprotein Not Available 0.002
2928 Genome polyprotein Not Available 0.002
3160 Genome polyprotein Not Available 0.002
3260 Genome polyprotein Not Available 0.002
4783 Genome polyprotein Not Available 0.002
5726 Genome polyprotein Not Available 0.002
5779 Genome polyprotein Not Available 0.002
5867 Genome polyprotein Not Available 0.002
6253 Genome polyprotein Not Available 0.002
6301 Genome polyprotein Not Available 0.002
6380 Genome polyprotein Not Available 0.002
6381 Genome polyprotein Not Available 0.002
6437 Genome polyprotein Not Available 0.002
6520 Genome polyprotein Not Available 0.002
6521 Genome polyprotein Not Available 0.002
6652 Genome polyprotein Not Available 0.002
6734 Genome polyprotein Not Available 0.002
6735 Genome polyprotein Not Available 0.002
6736 Genome polyprotein Not Available 0.002
6737 Genome polyprotein Not Available 0.002
6738 Genome polyprotein Not Available 0.002
6739 Genome polyprotein Not Available 0.002
6744 Genome polyprotein Not Available 0.002
6748 Genome polyprotein Not Available 0.002
6894 Genome polyprotein Not Available 0.002
6898 Genome polyprotein Not Available 0.002
706 Glutamate [NMDA] receptor subunit 3A GRIN3A 0.002
243 Ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 0.0019
5463 Calcium-activated potassium channel subunit beta 2 KCNMB2 0.0019
29 Tubulin beta-1 chain TUBB1 0.0019
6145 Solute carrier family 22 member 1 SLC22A1 0.0019
84 Nuclear receptor 0B1 NR0B1 0.0019
4666 Fucose-binding lectin PA-IIL lecB 0.0019
2372 Bifunctional tail protein 9 0.0019
4787 Envelope glycoprotein gp160 env 0.0019
4820 Envelope glycoprotein gp160 env 0.0019
5727 Envelope glycoprotein gp160 env 0.0019
4131 Prostaglandin E2 receptor, EP3 subtype PTGER3 0.0018
1457 Long-chain-fatty-acid--CoA ligase 4 ACSL4 0.0018
406 Prostaglandin E2 receptor, EP2 subtype PTGER2 0.0018
469 Annexin A1 ANXA1 0.0018
6167 Organic solute transporter subunit beta OSTB 0.0018
6166 Organic solute transporter subunit alpha OSTA 0.0018
467 Delta-type opioid receptor OPRD1 0.0018
1192 Sulfotransferase 1A1 SULT1A1 0.0018
2577 Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase MAN1B1 0.0018
1757 Myeloperoxidase MPO 0.0017
3480 Mannan endo-1,4-beta-mannosidase manA 0.0017
64 Neuraminidase NA 0.0017
641 Neuraminidase NA 0.0017
2676 Neuraminidase NA 0.0017
3026 Neuraminidase NA 0.0017
3519 Neuraminidase NA 0.0017
6007 Neuraminidase NA 0.0017
595 Fibrinogen alpha chain FGA 0.0017
465 Calmodulin CALM1 0.0017
6014 Cytochrome P450 2A13 CYP2A13 0.0017
1782 Neutrophil gelatinase-associated lipocalin LCN2 0.0017
1439 Lactotransferrin LTF 0.0017
6181 UDP-glucuronosyltransferase 1-8 UGT1A8 0.0016
1243 Cathepsin D CTSD 0.0016
6148 Multidrug resistance-associated protein 7 ABCC10 0.0016
6177 UDP-glucuronosyltransferase 1-10 UGT1A10 0.0016
73 Prostaglandin E2 receptor, EP1 subtype PTGER1 0.0016
1709 Canalicular multispecific organic anion transporter 2 ABCC3 0.0016
2430 Chondroitinase B cslB 0.0016
958 Insulin-like growth factor 1 receptor IGF1R 0.0016
514 Potassium voltage-gated channel subfamily H member 6 KCNH6 0.0015
772 Potassium voltage-gated channel subfamily H member 7 KCNH7 0.0015
6307 Ig gamma-2 chain C region IGHG2 0.0015
309 Antithrombin-III SERPINC1 0.0015
2581 Chondroitinase AC cslA 0.0015
6847 Lactase-phlorizin hydrolase LCT 0.0015
6160 Solute carrier organic anion transporter family member 3A1 SLCO3A1 0.0015
6500 Phospholipase A2 PLA2G1B 0.0015
6153 Solute carrier organic anion transporter family member 4A1 SLCO4A1 0.0015
6157 Solute carrier organic anion transporter family member 1B3 SLCO1B3 0.0014
2207 Rhodopsin RHO 0.0014
2222 Equilibrative nucleoside transporter 1 SLC29A1 0.0014
6152 Solute carrier organic anion transporter family member 2A1 SLCO2A1 0.0014
610 Calcium-activated potassium channel subunit alpha 1 KCNMA1 0.0014
6158 Solute carrier organic anion transporter family member 1C1 SLCO1C1 0.0014
468 Cytochrome P450 4A11 CYP4A11 0.0014
6136 Multidrug resistance-associated protein 5 ABCC5 0.0013
4785 Ig gamma-1 chain C region IGHG1 0.0013
6176 UDP-glucuronosyltransferase 1-3 UGT1A3 0.0013
6141 Sodium/bile acid cotransporter SLC10A1 0.0013
76 Nitric-oxide synthase, brain NOS1 0.0013
6018 UDP-glucuronosyltransferase 1-9 UGT1A9 0.0012
6178 UDP-glucuronosyltransferase 2B7 UGT2B7 0.0012
1632 Solute carrier organic anion transporter family member 2B1 SLCO2B1 0.0012
101 Potassium voltage-gated channel subfamily H member 2 KCNH2 0.0012
238 Peroxisome proliferator-activated receptor gamma PPARG 0.0012
1024 Solute carrier family 22 member 11 SLC22A11 0.0011
952 Dipeptidyl peptidase 4 DPP4 0.0011
2164 Multidrug resistance-associated protein 4 ABCC4 0.0011
833 Organic cation/carnitine transporter 1 SLC22A4 0.0011
6147 Solute carrier family 22 member 3 SLC22A3 0.0011
291 Nitric-oxide synthase, endothelial NOS3 0.0011
6144 Solute carrier family 22 member 2 SLC22A2 0.001
1729 Solute carrier family 22 member 6 SLC22A6 0.0009
↑